Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for Akt 1
Most Correlated Studies
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
- L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
- L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
Most Relevant Literature
- Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer.
- Role of phospholipase D in the lifespan of Caenorhabditis elegans.
- High-Protein Mulberry Leaves Improve Glucose and Lipid Metabolism via Activation of the PI3K/Akt/PPA…
- The Bufei Nashen pill inhibits the PI3K/AKT/HIF-1 signaling pathway to regulate extracellular matrix…
- Veronica linariifolia subsp. dilatata ameliorates LPS-induced acute lung injury by attenuating endot…
Most Relevant Clinical Trials
- Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
- Autonomic Phenotype Before and After Akt Inhibition
- Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Ca…
- Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Remov…
- Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
